Oxigene Inc fka OXGN

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

PennyStock Alert Free

09/24/19 6:19 PM

Post #1,175

Re: #1,174: @PennyStock Alert - What's the deal here? According to my calculations

No changes

PennyStock Alert Free

09/17/19 11:40 AM

Post #1,174

What's the deal here? According to my calculations the buy out in March should be atleast $1.30 if the revenue keeps up.

Neuronal

12/01/16 8:16 PM

Post #1,173

Re: #1,171: @gi197845 - I think OXGN/MATN has moved for you, what's

Lol, don't know I haven't looked for quite awhile. Wouldn't be surprised though.

MATN

gi197845

12/01/16 8:15 PM

Post #1,172

Re: #1,168: @ash111 - OXGN/MATN Solid day here.all my stocks w/upside potential

How's that solid balance sheet doing for ya, Ash?

gi197845

12/01/16 8:14 PM

Post #1,171

Re: #1,170: @Neuronal - We received a US patent this morning and

I think OXGN/MATN has moved for you, what's it at now, .40?

Neuronal

10/10/16 10:52 AM

Post #1,170

We received a US patent this morning and minimal movement????

MATN

ash111

06/20/16 3:03 PM

Post #1,169

84 cents +15%.

ash111

06/20/16 2:11 PM

Post #1,168

OXGN/MATN Solid day here.all my stocks w/upside potential backup w/solid balance sheet.

Fibanotch

06/20/16 11:57 AM

Post #1,167

Re: #1,164: @MyVinylCreations - It only went down by .0001 not really

Jiminy Cricket Free

06/20/16 9:24 AM

Post #1,166

OXGN new ticker is MATN

ash111

06/18/16 4:35 PM

Post #1,165

Re: #1,164: @MyVinylCreations - It only went down by .0001 not really

8k out after hours.no change.RM brewing?

MyVinylCreations Free

06/18/16 2:02 PM

Post #1,164

Re: #1,163: @Fibanotch - WHY? ...That is what I'm asking.

It only went down by .0001 not really consider tanking.

Fibanotch

06/18/16 10:51 AM

Post #1,163

Re: #1,162: @ash111 - Why tanking? Name Change http://ih.advfn.com/p.php?pid=nmona&article=71761109

WHY? ...That is what I'm asking.

ash111

06/17/16 9:13 PM

Post #1,162

Re: #1,159: @Fibanotch - do u c this tanking a bit ..after

Why tanking? Name Change http://ih.advfn.com/p.php?pid=nmona&article=71761109

MyVinylCreations Free

06/17/16 8:45 PM

Post #1,161

Here is the link to the 8k
http://investor.oxigene.com/secfiling.cfm?filingID=1193125-16-624954&CIK=908259

MyVinylCreations Free

06/17/16 8:28 PM

Post #1,160

Re: #1,158: @ash111 - OXGN 8k out

Can you post link? Thanks

Fibanotch

06/17/16 7:19 PM

Post #1,159

Re: #1,158: @ash111 - OXGN 8k out

do u c this tanking a bit ..after recent 8k?

ash111

06/17/16 4:53 PM

Post #1,158

Re: #1,154: @ash111 - On sticky DD

OXGN 8k out

ash111

06/17/16 4:53 PM

Post #1,157

Re: #1,154: @ash111 - On sticky DD

OXGN 8k out

rnoutlaw21 Free

06/16/16 3:53 PM

Post #1,156

Re: #1,154: @ash111 - On sticky DD

Thx. Was on mobile can't see that

rnoutlaw21 Free

06/16/16 3:52 PM

Post #1,155

Re: #1,154: @ash111 - On sticky DD

Thx. Was on mobile can't see that

ash111

06/16/16 3:45 PM

Post #1,154

Re: #1,152: @rnoutlaw21 - Ash, is there a near term catalyst here?

On sticky DD

MyVinylCreations Free

06/16/16 3:20 PM

Post #1,153

We just need a little more volume and this shall fly

rnoutlaw21 Free

06/16/16 2:40 PM

Post #1,152

Re: #1,130: @ash111 - OXGN i expect a big jump over a buck.

Ash, is there a near term catalyst here?

ash111

06/13/16 12:51 PM

Post #1,151

Re: #1,149: @Neuronal - I'm pretty shocked at the lack of movement

I have no explanation for that.

Neuronal

06/13/16 12:48 PM

Post #1,149

Re: #1,148: @ash111 - $18m cap,rare solid balance sheet vs $1B +

I'm pretty shocked at the lack of movement and interest in this stock with the facts that you've pointed out, as well as the orphan drug granted by the FDA (which was huge). Thoughts on the sluggishness??

OXGN

ash111

06/13/16 10:48 AM

Post #1,148

Re: #1,147: @MyVinylCreations - Pre-market is looking good here!!!

$18m cap,rare solid balance sheet vs $1B + market: http://www.mordorintelligence.com/industry-reports/ovarian-cancer-diagnostics-and-therapeutics-market?gclid=CPLBv_2epc0CFTMo0wodS5ALxg

Assets/debt ratio=12 very solid,RARE,Net Assets(total assets minus total liabilities)= $22m. vs $18m cap.

Co. received a Fast Track + Orphan Drug. FDA very impressed.this is a $10+ stock on the works imo.

MyVinylCreations Free

06/13/16 7:27 AM

Post #1,147

Pre-market is looking good here!!!

Oceanfreedom Free

06/10/16 4:58 PM

Post #1,146

Re: #1,145: @TradeFlow - Smit and Ash on the same board. What

lol. Thought exact same thing. Took a position today because of PR and Ash DD. Was hoping for more today but will hold longer because of DD and your post.

TradeFlow

06/10/16 4:18 PM

Post #1,145

Smit and Ash on the same board. What oh what do we have here. Reading over the weekend!

ash111

06/10/16 3:31 PM

Post #1,144

sweet http://stockcharts.com/h-sc/ui?s=OXGN

MyVinylCreations Free

06/10/16 3:01 PM

Post #1,143

I am hoping to catch some more at .76-77 range today.. But staying here for a while!!!

ash111

06/10/16 1:49 PM

Post #1,141

Re: #1,140: @buckiii2 - Thanks ASH. I picked some up around .74.Hope

solid data,solid day.im here to stay, no intention to sell,it's like giving a gold away from you

buckiii2

06/10/16 1:41 PM

Post #1,140

Re: #1,129: @ash111 - OXGN holding tight,too cheap.gonna break a buck sooner

Thanks ASH. I picked some up around .74.Hope you don't kick us to the curb like someone else we know!

ming1234

06/10/16 12:27 PM

Post #1,139

it should catch more volume later today and following week monday with this good news

ash111

06/10/16 12:07 PM

Post #1,138

OXGN 93k buy .80

ash111

06/10/16 11:23 AM

Post #1,137

Re: #1,135: @Neuronal - Agree, and amazing news today. I just can't

OXGN acting as it should.very steady and defiantly a long term hold for me.posted several reasons.a Fast Track +Orphan Drug. go to FDA website.it's not so easy to receive a fast track. even at $10 cap will be very reasonable imo( about $200m).
Assets/debt ratio=12 very solid(even rare),Net Assets(total assets minus total liabilities)= $22m. currently trading at $18m cap.

ash111

06/10/16 11:22 AM

Post #1,136

Re: #1,127: @Talc Moan - $5.00+ stock by end of the year if

Totally agree .nice to see good traders finding this opp as well.

Neuronal

06/10/16 11:14 AM

Post #1,135

Re: #1,129: @ash111 - OXGN holding tight,too cheap.gonna break a buck sooner

Agree, and amazing news today. I just can't believe it hasn't moved past $1 already today. Surprised by the lack of response.

OXGN

ash111

06/10/16 10:14 AM

Post #1,134

Re: #1,133: @tongly - this should be over 1 by now

OXGN this is a $10 stock on the works imo. "Showing superior effectiveness, effect on serious outcomes or improved effect on serious outcomes
Avoiding serious side effects of an available therapy
Improving the diagnosis of a serious condition where early diagnosis results in an improved outcome
Decreasing a clinical significant toxicity of an available therapy that is common and causes discontinuation of treatment
Ability to address emerging or anticipated public health need"

http://www.fda.gov/ForPatients/Approvals/Fast/ucm405399.htm

cap is under $20m and the balance sheet very solid,even rare.assets/debt ratio=12!!

tongly

06/10/16 10:13 AM

Post #1,133

Re: #1,132: @ash111 - it's a low floater. Fast Track status to

this should be over 1 by now

ash111

06/10/16 10:10 AM

Post #1,132

Re: #1,131: @tongly - need more volume

it's a low floater. Fast Track status to CA4P+Orphan Drug .FDA very impressed.this is a $10 stock potential imo.

tongly

06/10/16 9:58 AM

Post #1,131

Re: #1,130: @ash111 - OXGN i expect a big jump over a buck.

need more volume

ash111

06/10/16 9:54 AM

Post #1,130

Re: #1,129: @ash111 - OXGN holding tight,too cheap.gonna break a buck sooner

OXGN i expect a big jump over a buck.

ash111

06/10/16 9:50 AM

Post #1,129

OXGN holding tight,too cheap.gonna break a buck sooner or later.lots of upside potential here. see my others DD's all solid including financials ratio,CBIO, on fire as well.

ash111

06/10/16 9:26 AM

Post #1,128

Re: #1,118: @ash111 - OXGN All in one DD: P2 Study of

OXGN As of May 6, 2016, there were 26,544,934 shares of the Registrant’s Common Stock issued and outstanding,

Market Value $17,785,106 a/o Jun 09, 2016

Talc Moan

06/10/16 9:11 AM

Post #1,127

Re: #1,126: @ash111 - Great for this low floater w/very solid and

$5.00+ stock by end of the year if not more.

ash111

06/10/16 9:11 AM

Post #1,126

Re: #1,125: @Talc Moan - OXiGENE Receives U.S. Orphan Drug Designation for CA4P

Great for this low floater w/very solid and rare balance sheet.sticky DD.

Talc Moan

06/10/16 8:50 AM

Post #1,125

OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

Source: GlobeNewswire Inc.

OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of glioma. The designation provides for seven years of marketing exclusivity following product approval. CA4P has previously received orphan drug designation from the FDA for the treatment of ovarian cancer, neuroendocrine tumors and certain thyroid cancers.
Glioma is a broad category of brain tumors that grow from glial cells, and includes glioblastoma multiforme (GBM), which is particularly aggressive and often spreads quickly. OXiGENE has preclinical data that demonstrate a positive treatment effect of CA4P in GBM models.

“I am pleased that the FDA has provided orphan designation to CA4P for the treatment of glioma,” stated William D. Schwieterman, M.D., President and Chief Executive Officer of OXiGENE. “While the principal focus of our clinical development program remains on ovarian cancer, we continue to expand the potential indications and improve our proprietary position for CA4P as part of our novel platform of vascular targeted therapies in oncology.”

Orphan designation can be granted by the FDA to product candidates that are intended to treat rare diseases that generally affect fewer than 200,000 people in the United States.

About OXiGENE

OXiGENE is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy in orphan oncology indications. Vascular targeted therapy includes vascular disrupting agents (VDAs), such as the investigational drugs that OXiGENE is developing, and anti-angiogenic agents (AAs), a number of which are approved and widely used in oncology indications.

OXiGENE’s VDAs selectively obstruct a tumor’s blood supply without obstructing the blood supply to normal tissues, and treatment with our VDAs has been shown to lead to significant central tumor necrosis. The company believes that the treatment of cancer would be significantly improved if VDAs and AAs are used together, due to their complementary mechanisms of action. In combination, the VDA would occlude the blood vessels in the interior of a tumor while the AA would prevent the formation of new tumor blood vessels.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to pursue and continue development of our programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Investor and Media Contact:
ir@oxigene.com
650-635-7000
Primary Logo

Talc Moan

06/10/16 8:07 AM

Post #1,124

Re: #1,123: @ash111 - I don't hold for a specific PT. waiting

Big gap today!

Older

Oxigene Inc fka OXGN

Followers	86	Posters	271
Posts (Today)	0	Posts (Total)	1175
Created	07/29/03	Type	Free
Moderators

http://www.oxigene.com/about/companyinfo.asp

http://finance.yahoo.com/q/h?s=OXGN

OXiGENE, Inc., a biopharmaceutical company, engages in the development of novel small-molecule therapeutics to treat cancer and eye diseases. The company focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. It develops vascular disrupting agents (VDAs) and ortho-quinone prodrugs (OQPs). It develops VDAs for indications in oncology and ophthalmology; and OQPs for indications in oncology. The company?s products are in various clinical and preclinical trials for oncology and ophthalmology, as a single-agent and in combination with other therapies, including chemotherapy, radiotherapy, antibody therapy, and anti-vascular endothelial growth factor therapy. The company has collaborations with a various university and research institutions, including Gray Cancer Institute, Middlesex, the United Kingdom; Baylor University, Waco, Texas; Arizona State University, Tempe, Arizona; The University of Texas MD Anderson Cancer Center, Houston, Texas; and Beth Israel Deaconess Medical Center, Boston, Massachusetts. The company was incorporated in 1988 and is headquartered in Waltham, Massachusetts.

>